CORRECTION: Tempest Therapeutics Q2 EPS $(0.54) Misses $(0.52) Estimate
Portfolio Pulse from Benzinga Newsdesk
Tempest Therapeutics reported Q2 earnings per share (EPS) of $(0.54), missing the estimated $(0.52).
August 10, 2023 | 9:02 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Tempest Therapeutics' Q2 earnings per share (EPS) of $(0.54) missed the estimated $(0.52).
Earnings reports are a key indicator of a company's financial health. A miss on earnings estimates can lead to a negative market reaction, potentially causing the stock price to drop in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100